Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer

Surg Oncol. 2015 Mar;24(1):28-34. doi: 10.1016/j.suronc.2014.11.002. Epub 2014 Nov 20.

Abstract

It has been shown that chemotherapy has limited antitumor activity against advanced urothelial bladder cancer (UBC). Consequently, there is an urgent need to develop effective therapeutic methods for patients with advanced UBC. In the present study, the inhibitory effects of lentinan alone, gemcitabine alone, or lentinan combined with gemcitabine on the proliferation of the UBC cell line, T24, were investigated. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, annexin V fluorescein isothiocyanate/propidium iodide staining, and flow cytometry were used to determine the proliferation and apoptosis of T24 cells in each treatment group. Survival-related protein expression was analyzed by western blotting. Increased concentrations of lentinan, or lentinan combined with gemcitabine, positively correlated with decreased T24 cell proliferation. Lentinan combined with gemcitabine chemotherapy significantly inhibited UBC cell proliferation. Gemcitabine has the ability to induce T24 cell apoptosis, and this effect is enhanced when it is combined with lentinan.

Keywords: Apoptosis; Gemcitabine; Lentinan; Proliferation; Urothelial bladder cancer.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antimetabolites, Antineoplastic / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols
  • Apoptosis / drug effects
  • Cell Line, Tumor
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Lentinan / pharmacology*
  • Urinary Bladder Neoplasms / drug therapy*
  • Urothelium / pathology

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Deoxycytidine
  • Lentinan
  • gemcitabine